Kite Pharma Inc. (NASDAQ:KITE)‘s stock had its “buy” rating reaffirmed by Jefferies Group in a report released on Thursday.

The analysts wrote, “Analysts Offer Insights on Healthcare Companies: Kite Pharma (NASDAQ: KITE), Magellan Health (NASDAQ: MGLN) and Array Biopharma (NASDAQ: ARRY) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=07a193bd66&wpp_id=459551’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Offer Insights on Healthcare Companies: Kite Pharma (NASDAQ: KITE), Magellan Health (NASDAQ: MGLN) and Array Biopharma (NASDAQ: ARRY)”

KITE has been the topic of a number of other research reports. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $70.00 target price on shares of Kite Pharma in a research note on Monday, October 10th. Vetr lowered Kite Pharma from a “strong-buy” rating to a “buy” rating and set a $63.91 target price on the stock. in a research note on Tuesday, September 13th. Stifel Nicolaus reiterated a “buy” rating and issued a $74.00 target price on shares of Kite Pharma in a research note on Thursday, September 22nd. BTIG Research reiterated a “neutral” rating on shares of Kite Pharma in a research note on Sunday, October 9th. Finally, Barclays PLC increased their target price on Kite Pharma from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 27th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $73.03.

Analyst Recommendations for Kite Pharma (NASDAQ:KITE)

Kite Pharma (NASDAQ:KITE) opened at 49.61 on Thursday. Kite Pharma has a 52-week low of $38.41 and a 52-week high of $89.84. The stock’s market cap is $2.46 billion. The stock has a 50 day moving average price of $50.28 and a 200 day moving average price of $51.95.

Kite Pharma (NASDAQ:KITE) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($1.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.63) by $0.14. Kite Pharma had a negative return on equity of 32.91% and a negative net margin of 873.86%. The company had revenue of $7.34 million for the quarter, compared to analyst estimates of $4.94 million. During the same quarter in the prior year, the firm posted ($0.38) EPS. Kite Pharma’s quarterly revenue was up 43.1% compared to the same quarter last year. Analysts expect that Kite Pharma will post ($5.85) EPS for the current fiscal year.

In other Kite Pharma news, COO Cynthia M. Butitta sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $54.13, for a total value of $541,300.00. Following the completion of the sale, the chief operating officer now owns 105,477 shares of the company’s stock, valued at $5,709,470.01. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Helen Susan Kim sold 35,900 shares of the firm’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $60.27, for a total value of $2,163,693.00. Following the completion of the sale, the executive vice president now directly owns 42,500 shares of the company’s stock, valued at approximately $2,561,475. The disclosure for this sale can be found here. 20.60% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the company. First Republic Investment Management Inc. boosted its position in shares of Kite Pharma by 101.1% in the first quarter. First Republic Investment Management Inc. now owns 739,867 shares of the biopharmaceutical company’s stock valued at $33,967,000 after buying an additional 372,034 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Kite Pharma by 7.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 956,903 shares of the biopharmaceutical company’s stock valued at $43,931,000 after buying an additional 62,968 shares during the last quarter. State Street Corp boosted its position in shares of Kite Pharma by 30.6% in the first quarter. State Street Corp now owns 1,332,147 shares of the biopharmaceutical company’s stock valued at $61,162,000 after buying an additional 312,481 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of Kite Pharma by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,364 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 651 shares during the last quarter. Finally, Moody Aldrich Partners LLC purchased a new position in shares of Kite Pharma during the second quarter valued at about $694,000. 75.34% of the stock is owned by institutional investors and hedge funds.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

5 Day Chart for NASDAQ:KITE

Receive News & Stock Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related stocks with our FREE daily email newsletter.